Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Mimedx (MDXG) over the last 15 years, with Q3 2025 value amounting to $318000.0.

  • Mimedx's Amortizatization of Intangibles rose 6562.5% to $318000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 2648.81%. This contributed to the annual value of $1.3 million for FY2024, which is 331.23% up from last year.
  • According to the latest figures from Q3 2025, Mimedx's Amortizatization of Intangibles is $318000.0, which was up 6562.5% from $312000.0 recorded in Q2 2025.
  • Over the past 5 years, Mimedx's Amortizatization of Intangibles peaked at $338000.0 during Q4 2024, and registered a low of $173000.0 during Q2 2022.
  • Moreover, its 5-year median value for Amortizatization of Intangibles was $265000.0 (2021), whereas its average is $256894.7.
  • In the last 5 years, Mimedx's Amortizatization of Intangibles plummeted by 3007.25% in 2021 and then soared by 6562.5% in 2025.
  • Over the past 5 years, Mimedx's Amortizatization of Intangibles (Quarter) stood at $265000.0 in 2021, then rose by 23.77% to $328000.0 in 2022, then dropped by 5.79% to $309000.0 in 2023, then rose by 9.39% to $338000.0 in 2024, then dropped by 5.92% to $318000.0 in 2025.
  • Its Amortizatization of Intangibles was $318000.0 in Q3 2025, compared to $312000.0 in Q2 2025 and $307000.0 in Q1 2025.